ArticleCurrent microbiology2022
Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies.
Article in Current microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Extending ImmunoSpotVaccines · 2026Article
- Fetal vascular malperfusion and other placental lesions in relation to maternal SARS-CoV-2 exposure: a case-control study.Frontiers in medicine · 2026Article
- Persistence of SARS-CoV-2 S IgG Antibodies in Children Post-COVID-19 and the Association of Antibody Levels with Vaccination Status.Current microbiology · 2025Article
- Assessment of the prevalence of respiratory pathogens and the level of immunity to respiratory viruses in soldiers and civilian military employees in Poland.Respiratory research · 2025Article
- Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate.Biomedicines · 2025Article
- A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population.PloS one · 2025Article
- Dynamics of SARS-CoV-2 antibodies after natural infection: insights from a study on Pasteur Institute of Tunis employees.The Libyan journal of medicine · 2024Article
- Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico.Scientific reports · 2024Article
- Article
- A novel approach to designing viral precision vaccines applied to SARS-CoV-2.Frontiers in cellular and infection microbiology · 2024Article
- Article
- Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination.Emerging microbes & infections · 2023Article
- Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection.Iranian journal of microbiology · 2023Article
- Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19.Heliyon · 2023Article
- Behavior of immunoglobulin G antibodies for SARS-COV-2 in Mexican pediatric patients with comorbidities: a prospective comparative cohort study.Translational pediatrics · 2023Article
- Cross-reactive humoral and CD4Frontiers in immunology · 2023Article
- Article
- Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective.Frontiers in immunology · 2023Review
- Evaluation of Free Light Chains (FLCs) Synthesis in Response to Exposure to SARS-CoV-2.International journal of molecular sciences · 2022Article
- Dynamic changes of serum SARS-CoV-2 antibody levels in COVID-19 patients.The Journal of infection · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Antibodies against severe acute respiratory syndrome coronavirus-2 (Anti-SARS-COV-2) can be detected in patients with COVID-19 in 7 to 10 days post onset of symptoms (POS). However, there is no firm evidence of the long-term persistence of these antibodies in recovered COVID-19 patients. Therefore, this study aimed to evaluate the stability of anti-SARS-COV-2 IgG in recovered COVID-19 patients in a 15-month follow-up testing. Thirty hospitalized patients with real-time PCR-confirmed SARS-COV-2 infections were included in the study and five serum samples (1st, 2nd, 3rd, 4th, and 5th) were collected from each participant. The serum levels of N and S specific anti-SARS-COV-2 IgG and IgM antibodies were evaluated by the immunoassay technique at the same time. To determine the correlation between levels of anti-SARS-CoV-2 IgG/IgM with severity of disease, neutrophil-to-lymphocyte ratio (NLR %), and the serum levels of C-reactive protein were evaluated using an automated analyzer and turbidimetry assays, respectively. The mean serum level of anti-SARS-CoV-2 IgG antibody was at the highest level up to 90 days and then decreased significantly 1 year POS (P < 0.0001). However, it was still detectable in a 15-month follow-up testing. There were no significant differences in the mean levels of IgG antibody in patients with mild, moderate, and severe diseases. The results from this study suggest that the titer of anti-SARS-COV-2 IgG antibody is detectable at high levels up to 3 months and then decreases over time. However, these antibodies can be reliably detected in up to 15 months, and they may persist for a long time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.